Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 4/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7466206 | 0.82 | MAPK14 (0.36) | MEN1KMT2AMAPK14BACE1LTA4H | |
| SCHEMBL7470568 | 0.81 | MAPK14 (0.38) | MEN1KMT2AMAPK14BACE1CYP11B1 | |
| SCHEMBL6697614 | 0.80 | MEN1 (0.39) | MEN1KMT2ALIPEMAPK14BACE1 | |
| SCHEMBL6695270 | 0.78 | MEN1 (0.38) | MEN1KMT2ALIPEMAPK14BACE1 | |
| SCHEMBL6695269 | 0.78 | MEN1 (0.38) | MEN1KMT2ALIPEMAPK14BACE1 | |
| SCHEMBL6695411 | 0.77 | RAB9A (0.35) | MEN1KMT2ALMNA | |
| SCHEMBL6692299 | 0.76 | MEN1 (0.37) | MEN1KMT2ALIPEMAPK14CYP11B1 | |
| SCHEMBL6692302 | 0.76 | MEN1 (0.37) | MEN1KMT2ALIPEMAPK14CYP11B1 | |
| SCHEMBL8544631 | 0.76 | MAPK14 (0.37) | MAPK14LTA4H | |
| SCHEMBL7467262 | 0.75 | MAPK14 (0.39) | KMT2AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023806-A1 | N-phenylcarbamates having a microbicide insecticide and acaricide effect | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | claimed |
| US-20040023806-A1 | N-phenylcarbamates having a microbicide insecticide and acaricide effect | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023806-A1 | N-phenylcarbamates having a microbicide insecticide and acaricide effect | CBR3, CBR1, CYP1B1 | MEN1 3045/4885KMT2A 3292/4885LIPE 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.